A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
Open Access
- 6 March 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (5) , 1521
Abstract
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investigate a combined biomarker with prognostic or predictive value in ES-SCLC. We determined the best independent prognostic biomarker among the four complete blood-count-derived inflammatory biomarkers (CBC-IBs). Subsequently, we analyzed the prognostic or predictive value of combining this independent CBC-IB with PD-L1 (SP142) expression. We prospectively assessed the SP142 analyses in tumor samples at diagnosis. Results: All in all, 55 patients with ES-SCLC were classified into four groups according to the systemic immune inflammation index (SII) (low/high) and SP142 (positive/negative). The best survival was observed in the low-SII/ SP142-positive group, whereas the worst survival was observed in the high-SII/SP142-negative group (p = 0.002). The combined SII-SP142 biomarker was better for predicting both survival and disease progression in patients with ES-SCLC. Conclusions: The combined SII-SP142 biomarker can be readily and universally obtained at a low cost in clinical practice, without requiring advanced genomics technology or specialized expertise. Although further studies are needed to confirm that the combined SII-SP142 biomarker is widely applicable, it should help clinicians to identify the best patients for combined chemotherapy with atezolizumab in ES-SCLC.Keywords
Funding Information
- Inha University (67927)
This publication has 36 references indexed in Scilit:
- Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta‑analysisClinical and Experimental Medicine, 2023
- SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early DetectionJournal of Thoracic Oncology, 2022
- Small cell lung cancer: Novel treatments beyond immunotherapySeminars in Cancer Biology, 2022
- Small cell lung cancer: a slightly less orphan disease after immunotherapyAnnals of Oncology, 2021
- Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesJournal of Thoracic Oncology, 2020
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2019
- Inflammation and Cancer: Triggers, Mechanisms, and ConsequencesImmunity, 2019
- Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the LungJournal of Thoracic Oncology, 2018
- Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: A systematic review and meta-analysisCancer Treatment Reviews, 2015
- Hallmarks of Cancer: The Next GenerationCell, 2011